KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Net Income (2016 - 2025)

Acadia Pharmaceuticals has reported Net Income over the past 16 years, most recently at $23.2 million for Q4 2025.

  • Quarterly results put Net Income at $23.2 million for Q4 2025, down 83.83% from a year ago — trailing twelve months through Dec 2025 was $140.7 million (down 37.89% YoY), and the annual figure for FY2025 was $140.7 million, down 37.88%.
  • Net Income for Q4 2025 was $23.2 million at Acadia Pharmaceuticals, down from $71.8 million in the prior quarter.
  • Over the last five years, Net Income for ACAD hit a ceiling of $143.8 million in Q4 2024 and a floor of -$113.1 million in Q1 2022.
  • Median Net Income over the past 5 years was -$6.7 million (2021), compared with a mean of -$3.9 million.
  • Biggest five-year swings in Net Income: crashed 139.49% in 2023 and later skyrocketed 2935.36% in 2024.
  • Acadia Pharmaceuticals' Net Income stood at -$43.1 million in 2021, then increased by 3.28% to -$41.7 million in 2022, then skyrocketed by 209.68% to $45.7 million in 2023, then skyrocketed by 214.46% to $143.8 million in 2024, then plummeted by 83.83% to $23.2 million in 2025.
  • The last three reported values for Net Income were $23.2 million (Q4 2025), $71.8 million (Q3 2025), and $26.7 million (Q2 2025) per Business Quant data.